Business
Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020
- Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing Phase 1 Clinical Trial of
About this update from Immunic, Inc.
[{"type":"text","content":"- Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing Phase 1 Clinical Trial of IMU-935 -\n - Live Webcast to be Held From 9:00 am to 1:00 pm ET -\n\n\n NEW YORK, May 19, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that it will host a virtual R&D Day today, May 19, 2020, from 9:00 am to 1:00 pm ET. Immunic's management and invited key opinion leaders, specializing in multiple sclerosis and inflammatory bowel disease, will discuss today's treatment options for, and the unmet medical needs of, chronic inflammatory and autoimmune diseases, as well as clinical progress of Immunic's selective oral immunology programs and their potential advantages over the current treatment landscape. Management will also discuss the company's coronavirus disease 2019 (COVID-19) program.\nDuring the event, Immunic will provide recently obtained preclinical data testing the company's lead asset, IMU-838, a selective oral DHODH inhibitor, against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), showing that, in in vitro models, IMU-838 is able to inhibit replication of clinical isolates of SARS-CoV-2, obtained from patients with COVID-19, at drug concentrations consistent with previously employed IMU-838 dosing regimens. Highlights will include:\nValidation of previously published antiviral data against SARS-CoV-2 in monkey Vero cells showing antiviral activity with EC90 of 7 µM Determination of strong antiviral activity in human lung epithelial cells infected with SARS-CoV-2 clinical isolates, achieving a virus reduction of 3-log units with 10 µM of IMU-838; EC50 concentrations are ranging between 1 and 6 µM in various assay systems Review of previously published IMU-838 pharmacokinetic data, showing that in earlier trials, steady state concentrations of 10-30 µM were reached, and that these dosing regimens have been associated with favorable safety and tolerability profiles in prior clinical data sets Insights into the anticipated multifold antiviral mode of action of IMU-838 by inhibiting viral replication, inducing innate immunity and dampening the excessive immune response thought to ...